Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability

Asad Umar(National Institutes of Health), C. Richard Boland(Baylor University Medical Center), Jonathan P. Terdiman(University of California, San Francisco), Sapna Syngal(National Institutes of Health), Albert de la Chapelle(The Ohio State University), Josef Rüschoff(Klinikum Kassel), Richard Fishel(Thomas Jefferson University), Noralene M. Lindor(Mayo Clinic), Lawrence J. Burgart(Mayo Clinic), Richard C. Hamelin(Institut National de Recherche en Santé Publique), Stanley R. Hamilton(The University of Texas Health Science Center at Houston), Robert A. Hiatt(University of California, San Francisco), Jeremy R. Jass(McGill University), Annika Lindblom(Karolinska Institutet), Henry T. Lynch(Creighton University), Païvi Peltomäki(University of Helsinki), Scott D. Ramsey(Fred Hutch Cancer Center), Miguel A. Rodrı́guez-Bigas(The University of Texas Health Science Center at Houston), Hans F. A. Vasen(Detection Limit (United States)), Ernest T. Hawk(National Institutes of Health), J. Carl Barrett(National Institutes of Health), Andrew N. Freedman(National Institutes of Health), Sudhir Srivastava(Dana-Farber Cancer Institute)
JNCI Journal of the National Cancer Institute
February 17, 2004
Cited by 3,177Open Access
Full Text

Abstract

Hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is a common autosomal dominant syndrome characterized by early age at onset, neoplastic lesions, and microsatellite instability (MSI). Because cancers with MSI account for approximately 15% of all colorectal cancers and because of the need for a better understanding of the clinical and histologic manifestations of HNPCC, the National Cancer Institute hosted an international workshop on HNPCC in 1996, which led to the development of the Bethesda Guidelines for the identification of individuals with HNPCC who should be tested for MSI. To consider revision and improvement of the Bethesda Guidelines, another HNPCC workshop was held at the National Cancer Institute in Bethesda, MD, in 2002. In this commentary, we summarize the Workshop presentations on HNPCC and MSI testing; present the issues relating to the performance, sensitivity, and specificity of the Bethesda Guidelines; outline the revised Bethesda Guidelines for identifying individuals at risk for HNPCC; and recommend criteria for MSI testing.


Related Papers

No related papers found

Powered by citation graph analysis